Korean J Urol.  2010 Jan;51(1):25-29.

Alteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer

• Hong SK
• Ko DW
• Park J
• Kim IS
• Doo SH
• Yoon CY
• Park H
• Lee WK
• Kim DS
• Jeong SJ
• Byun SS
• Lee SE

Abstract

PURPOSE
We performed a comparative analysis of the plasma levels of antithrombin (AT) III, plasminogen, fibrinogen, and D-dimer among patients with and without clinically localized prostate cancer to investigate the clinical significance of the coagulation profile in prostate cancer. MATERIALS AND METHODS: A prospective study was performed in which plasma levels of AT III, plasminogen, fibrinogen, and D-dimer were assessed in patients before they underwent prostate biopsy. According to the results of the biopsy, the patients were categorized into the cancer group or the control group. Levels of the four coagulation factors were then compared between the cancer and control groups. Also, levels of the four coagulation factors were correlated with tumor stage and grade in the cancer group. RESULTS: The cancer group had significantly lower levels of AT III activity and higher plasma D-dimer levels than did the control group (p=0.007 and p=0.018, respectively). Within the cancer group, no significant differences were observed in the levels of AT III, plasminogen, fibrinogen, or D-dimer between those with a pathological Gleason score of > or =7 and otherwise. Regarding pathologic stage of prostate cancer, the subjects with organ-confined disease and those with extraprostatic extension of a tumor demonstrated no significant differences in the preoperative levels of the four coagulation factors analyzed. CONCLUSIONS: Our results suggest that plasma levels of AT III and D-dimer are altered in patients with prostate cancer. Further study is needed to elucidate the underlying mechanism and clinical significances of such a phenomenon among patients with clinically localized prostate cancer.

Keyword

Prostatic neoplasms; Blood coagulation tests

MeSH Terms

Antithrombin III
Biopsy
Blood Coagulation Factors
Blood Coagulation Tests
Fibrin Fibrinogen Degradation Products
Fibrinogen
Humans
Neoplasm Grading
Plasma
Plasminogen
Prospective Studies
Prostate
Prostatic Neoplasms
Antithrombin III
Blood Coagulation Factors
Fibrin Fibrinogen Degradation Products
Fibrinogen
Plasminogen

Reference

1. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992. 18:353–372.

2. Constantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost. 1993. 69:406–414.

3. Donati MB, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol. 2001. 106:18–24.

4. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 1992. 11:237–248.

5. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999. 25:173–182.

6. Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis. 2008. 10:238–241.

7. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002. 86:389–395.

8. Koh SC, Tham KF, Razvi K, Oei PL, Lim FK, Roy AC, et al. Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost. 2001. 7:141–148.

9. Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 2004. 98:93–98.

10. Cao Y, Lundwall A, Gadaleanu V, Lilja H, Bjartell A. Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. Am J Pathol. 2002. 161:2053–2063.

11. Beecken WD, Bentas W, Engels K, Glienke W, Urbschat A, Jonas D, et al. Reduced plasma levels of coagulation factors in relation to prostate cancer. Prostate. 2002. 53:160–167.

12. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost. 2004. 92:185–190.

13. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001. 31:388–394.

14. Langer F, Chun FK, Amirkhosravi A, Friedrich M, Leuenroth S, Eifrig B, et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost. 2007. 97:464–470.

15. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007. 25:349–355.

16. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost. 2003. 29:301–308.

17. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000. 18:600–608.

18. Kim TH, Yang DY, Kim SY, Kim H, Yoo HS, Choi H, et al. Evaluation of the changes of coagulation-fibrinolysis system during transurethral resection of the prostate by thromboelastography. Korean J Urol. 1997. 38:1217–1222.

19. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem. 2000. 275:1521–1524.